When should you move beyond first-line therapy for depression?

Journal of Clinical Psychiatry

Volumn 71, Issue SUPPL. 1, 2010, Pages 16-20

  McIntyre, Roger S ^a,b  

^a UNIVERSITY OF TORONTO   (Canada)

^b UNIVERSITY HEALTH NETWORK   (Canada)

Author keywords

[No Author keywords available]

Indexed keywords

AMFEBUTAMONE; ANTIDEPRESSANT AGENT; APLENZIN; ATYPICAL ANTIPSYCHOTIC AGENT; CITALOPRAM; FLUOXETINE; LITHIUM CARBONATE; MIRTAZAPINE; REBOXETINE; UNCLASSIFIED DRUG; VENLAFAXINE;

CLINICAL TRIAL; DRUG CHOICE; DRUG EFFECT; DRUG EFFICACY; DRUG RESPONSE; ELECTROENCEPHALOGRAPHY; HUMAN; MAJOR DEPRESSION; PREDICTION; PRIORITY JOURNAL; PSYCHOTHERAPY; REMISSION; REVIEW;

ANTIDEPRESSIVE AGENTS; ANTIPSYCHOTIC AGENTS; DEPRESSIVE DISORDER, MAJOR; DRUG ADMINISTRATION SCHEDULE; DRUG THERAPY, COMBINATION; HUMANS; PSYCHIATRIC STATUS RATING SCALES; PSYCHOTHERAPY; REMISSION INDUCTION; RISK FACTORS; SEVERITY OF ILLNESS INDEX; TIME FACTORS;

EID: 78149324131     PISSN: 01606689     EISSN: None     Source Type: Journal    
DOI: 10.4088/JCP.9104su1c.03     Document Type: Review

References (40)

1. Hasin DS, Goodwin RD, Stinson FS, et al. Epidemiology of major depressive disorder: results from the National Epidemiologic Survey on Alcoholism and Related Conditions. Arch Gen Psychiatry. 2005;62(10):1097-1106. doi:10.101/archpsyc.62.10.1097 PubMed (Pubitemid 41396935)
2. Patten SB, Wang JL, Williams JV, et al. Descriptive epidemiology of major depression in Canada. Can J Psychiatry. 2006;51(2):84-90. PubMed
3. World Health Organization. The Global Burden of Disease: 2004 Update. Geneva, Switzerland: WHO Press; 2008. http://www.who.int/healthinfo/global- burden-disease/GBD-report-2004update-full.pdf. Accessed August 25, 2010.
4. Kessler RC, Merikangas KR, Wang PS. The prevalence and correlates of workplace depression in the national comorbidity survey replication. J Occup Environ Med. 2008;50(4):381-390. doi:10.1097/JOM.0b013e31816ba9b8 PubMed (Pubitemid 351521612)
5. Katon WJ. Clinical and health services relationships between major depression, depressive symptoms, and general medical illness. Biol Psychiatry. 2003;54(3):216-226. doi:10.1016/S06-323(03)0273-7 PubMed
6. Katon W, Lin EHB, Kroenke K. The association of depression and anxiety with medical symptom burden in patients with chronic medical illness. Gen Hosp Psychiatry. 2007;29(2):147-155. doi:10.1016/j.genhospsych.206.1.05 PubMed (Pubitemid 46320681)
7. McIntyre RS, Soczynska JK, Beyer JL, et al. Medical comorbidity in bipolar disorder: re-prioritizing unmet needs. Curr Opin Psychiatry. 2007;20(4):406-416. doi:10.1097/YCO.0b013e3281938102 PubMed
8. Anisman H, Merali Z, Hayley S. Neurotransmitter, peptide and cytokine processes in relation to depressive disorder: comorbidity between depression and neurodegenerative disorders. Prog Neurobiol. 2008;85(1):1-74. doi:10.1016/j.pneurobio.208.01.04 PubMed
9. Cizza G, Primma S, Coyle M, et al. Depression and osteoporosis: a research synthesis with meta-analysis. Horm Metab Res. 2010;42(7):467-482. doi:10.105/s-030-1252020 PubMed
10. Culpepper L. Why do you need to move beyond first-line therapy for major depression? J Clin Psychiatry. 2010;71(suppl 1):4-9.
11. Masand PS. Tolerability and adherence issues in antidepressant therapy. Clin Ther. 2003;25(8):2289-2304. doi:10.1016/S0149-2918(03)8020-5 PubMed
12. Lin EH, Von Korff M, Katon W, et al. The role of the primary care physician in patients' adherence to antidepressant therapy. Med Care. 1995;33(1):67-74. doi:10.1097/05650-195010-06 PubMed
13. Trivedi MH. Tools and strategies for ongoing assessment of depression: a measurement-based approach to remission. J Clin Psychiatry. 2009;70(suppl 6):26-31. doi:10.408/JCP.813su1c.04 PubMed
14. Gelenberg AJ. Using assessment tools to screen for, diagnose, and treat major depressive disorder in clinical practice. J Clin Psychiatry. 2010;71(suppl E1):e01.
15. McIntyre RS, Fulton KA, Bakish D, et al. The HAM-D7: a brief depression scale to distinguish antidepressant response from symptomatic remission. Prim Psychiatry. 2003;10(1):39-42. (Pubitemid 36536495)
16. Rush JA Jr, First MB, Blacker D, eds. Handbook of Psychiatric Measures. 2nd ed. Washington, DC: American Psychiatric Publishing, Inc; 2008.
17. Galen Research. Quality of Life in Depression Scale (QLDS). http://www.proqolid.org/proqolid/instruments/quality-of-life-in-depression- scale-qlds. Published July 2007. Accessed August 25, 2010.
18. Harmer CJ, O'Sullivan U, Favaron E, et al. Effect of acute antidepressant administration on negative affective bias in depressed patients. Am J Psychiatry. 2009;166(10):1178-1184. doi:10.176/api.ajp.209.09020149 PubMed
19. Szegedi A, Jansen WT, van Willigenburg APP, et al. Early improvement in the first 2 weeks as a predictor of treatment outcome in patients with major depressive disorder: a meta-analysis including 6562 patients. J Clin Psychiatry. 2009;70(3):344-353. doi:10.408/JCP.07m03780 PubMed
20. American Psychiatric Association. Diagnostic and Statistical Manual of Mental Disorders. Fourth Edition, Text Revision. Washington, DC: American Psychiatric Association; 2000.
21. Keller MB. Past, present, and future directions for defining optimal treatment outcome in depression: remission and beyond. JAMA. 2003; 289(23):3152-3160. doi:10.101/jama.289.23.3152 PubMed
22. Rush AJ, Trivedi MH, Wisniewski SR, et al. Acute and longer-term outcomes in depressed outpatients requiring one or several treatment steps: a STAR*D report. Am J Psychiatry. 2006;163(11):1905-1917. doi:10.176/api.ajp.163.1.1905 PubMed
23. Trivedi MH, Rush AJ, Wisniewski SR, et al, for the STAR*D Study Team. Evaluation of outcomes with citalopram for depression using measurement-based care in STAR*D: implications for clinical practice. Am J Psychiatry. 2006;163(1):28-40. doi:10.176/api.ajp.163.1.28 PubMed
24. Rost K, Smith JL, Dickinson M. The effect of improving primary care depression management on employee absenteeism and productivity: a randomized trial. Med Care. 2004;42(12):1202-1210. doi:10.1097/05650-204120-07 PubMed (Pubitemid 39627297)
25. Mykletun A, Overland S, Dahl AA, et al. A population-based cohort study of the effect of common mental disorders on disability pension awards. Am J Psychiatry. 2006;163(8):1412-1418. doi:10.176/api.ajp.163.8.1412 PubMed (Pubitemid 44464413)
26. Holma KM, Melartin TK, Haukka J, et al. Incidence and predictors of suicide attempts in DSM-IV major depressive disorder: a five-year prospective study. Am J Psychiatry. 2010;167(7):801-808. doi:10.176/api.ajp.2010.09050627 PubMed
27. Rush AJ, Trivedi MH, Wisniewski SR, et al, for the STAR*D Study Team. Bupropion-SR, sertraline, or venlafaxine-XR after failure of SSRIs for depression. N Engl J Med. 2006;354(12):1231-1242. doi:10.1056/NEJMoa052963 PubMed
28. Trivedi MH, Fava M, Wisniewski SR, et al, for the STAR*D Study Team. Medication augmentation after the failure of SSRIs for depression. N Engl J Med. 2006;354(12):1243-1252. doi:10.1056/NEJMoa052964 PubMed
29. Calabrese JR, Keck PE Jr, Macfadden W, et al. A randomized, doubleblind, placebo-controlled trial of quetiapine in the treatment of bipolar I or II depression. Am J Psychiatry. 2005;162(7):1351-1360. doi:10.176/api.ajp.162.7. 1351 PubMed
30. Tohen M, Vieta E, Calabrese J, et al. Efficacy of olanzapine and olanzapine-fluoxetine combination in the treatment of bipolar I depression [published correction appears in Arch Gen Psychiatry. 2004;61(2):176]. Arch Gen Psychiatry. 2003;60(11):1079-1088. doi:10.101/archpsyc.60.1.1079 PubMed
31. Shelton RC, Stahl SM. Risperidone and paroxetine given singly and in combination for bipolar depression. J Clin Psychiatry. 2004;65(12):1715-1719. doi:10.408/JCP.v65n1218 PubMed
32. Nelson JC, Papakostas GI. Atypical antipsychotic augmentation in major depressive disorder: a meta-analysis of placebo-controlled randomized trials. Am J Psychiatry. 2009;166(9):980-991. doi:10.176/api.ajp.209.09030312 PubMed
33. Cutler AJ, Montgomery SA, Feifel D, et al. Extended release quetiapine fumarate monotherapy in major depressive disorder: a placebo- and duloxetine-controlled study [published correction appears in J Clin Psychiatry. 2009;70(12):1729]. J Clin Psychiatry. 2009;70(4):526-539. doi:10.408/JCP. 08m04592 PubMed
34. Mathews J, Garcia KS, Mintun MA, et al. Antidepressant efficacy of olanzapine as monotherapy in major depressive disorder, without psychosis: a pilot study. Psychiatry Res. 2006;146(2):149-155. doi:10.1016/j.pscychresns.205. 08.03 PubMed
35. Pae CU, Serretti A, Patkar AA, et al. Aripiprazole in the treatment of depressive and anxiety disorders: a review of current evidence. CNS Drugs. 2008;22(5):367-388. doi:10.2165/023210-2082050-02 PubMed (Pubitemid 351508122)
36. Dhir A, Kulkarni SK. Risperidone, an atypical antipsychotic enhances the antidepressant-like effect of venlafaxine or fluoxetine: possible involvement of alpha-2 adrenergic receptors. Neurosci Lett. 2008;445(1):83-88. doi:10.1016/j.neulet.208.08.074 PubMed
37. Jensen NH, Rodriguiz RM, Caron MG, et al. N-desalkylquetiapine, a potent norepinephrine reuptake inhibitor and partial 5-HT1A agonist, as a putative mediator of quetiapine's antidepressant activity. Neuropsychopharmacology. 2008;33(10):2303-2312. doi:10.1038/sj.np.1301646 PubMed
38. Manning JS. What alternatives to first-line therapy for depression are effective? J Clin Psychiatry. 2010;71(suppl 1):10-15.
39. Blier P, Ward HE, Tremblay P, et al. Combination of antidepressant medications from treatment initiation for major depressive disorder: a double-blind randomized study. Am J Psychiatry. 2010;167(3):281-288. doi:10.176/api.ajp.209.09020186 PubMed
40. Leuchter AF, Cook IA, Marangell LB, et al. Comparative effectiveness of biomarkers and clinical indicators for predicting outcomes of SSRI treatment in Major Depressive Disorder: results of the BRITE-MD study. Psychiatry Res. 2009;169(2):124-131. doi:10.1016/j.psychres.209.06.04 PubMed